bluebird bio Inc (NAS:BLUE)
$ 0.9313 0.0263 (2.91%) Market Cap: 179.50 Mil Enterprise Value: 304.12 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 25/100

bluebird bio Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 06:30PM GMT
Release Date Price: $1.37 (-6.80%)
Eric Joseph J.P. Morgan;Biotech Analyst

Okay, great. Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan and our next presenting company. Bluebird bio. And to take us through the story is company's CTO, Andrew Obin chain there is a Q&A session after the presentation. Just raise your hand. We'll bring a mike over to you for those who have questions. And then for those who are tuning in via webcast, feel free to submit questions as well. We'll bring them up in Q&A. So with that, Andrew, thanks for joining us.

Andrew Obenshain bluebird bio
Inc - President, CEO & Director

Good morning.

Thank you, Eric, and welcome to everyone in the room and welcome to everyone on the webcast is as well. Bluebird is in a class of its own with the only company with three FDA approved gene therapies. Most recently, we added lift Kenya to that mixed with approval in December for sickle cell disease and with still of the most underserved populations in the US. And importantly, all of this puts us on a solid path to profitability in the near

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot